By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Incyte Corporation 

1801 Augustine Cut-Off

Wilmington  Delaware  19803  U.S.A.
Phone: 1-855-446-2983 Fax: n/a


SEARCH JOBS

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. Our first commercial product, Jakafi®, is approved in the U.S. for patients with intermediate or high-risk myelofibrosis and for patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea. We have a diverse and growing portfolio of product candidates, including both small and large molecules.

Science and Innovation

At Incyte, science drives success. Our world-class expertise, investment in sound and precise science, and our rigorous pursuit of R&D drive our efforts to identify new molecules with the potential to improve the lives of patients, make a difference in health care, and build sustainable value for all our stakeholders.

Patients

We are committed to positively impacting the lives of patients with cancer and other diseases. Our clinical research is held to the highest standards of scientific and ethical rigor and we strive to implement programs and initiatives to remove any possible barriers to access for our medicines.

Compliance and Transparency

We aim to make a difference—for patients, medical professionals, organizations, the broader healthcare community and all our global stakeholders. To achieve these goals, we are committed to conducting business ethically. We hold ourselves accountable to the highest standards to ensure that all of our interactions are conducted appropriately. We regularly review and amend our practices according to our own standards, as well as the standards required of us by the communities in which we live and work.

Our Global Community

We exist to improve the lives of people facing life-altering and life-threatening diseases like cancer, and actively support various local and global initiatives that are health-related or benefit the communities in which we live and work.

We strive to comply with all laws and regulations that govern environmental, health and safety matters and to sustainable business practices.


Key Statistics


Email:
Ownership: Public

Web Site: Incyte
Employees:
Symbol: INCY
 









Company News
Incyte (INCY) Analyst And Investor Event To Highlight Clinical Data Presentations From ASCO 2017 6/5/2017 1:21:39 PM
Incyte (INCY) Release: Combination Of Epacadostat Plus Keytruda (Pembrolizumab) Demonstrates Activity In Clinical Trial Of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) 6/5/2017 11:16:36 AM
Updated Data From ECHO-202 Trial Of Incyte (INCY)’s Epacadostat In Combination With Merck & Co. (MRK)’s KEYTRUDA (Pembrolizumab) Demonstrate Clinical Activity Across Multiple Tumor Types 6/5/2017 7:42:39 AM
Incyte (INCY) Release: Clinical Trial Data For Combination Of Epacadostat And Opdivo (Nivolumab) Demonstrate Durable Clinical Responses In Patients With Melanoma And Head And Neck Cancer 6/5/2017 6:48:16 AM
Questions Rise As Incyte (INCY) Omits Response Rate Data From Several Patients Enrolled In IDO Lung Cancer Study 6/5/2017 6:13:22 AM
Incyte (INCY) To Present At Upcoming Investor Conferences 5/23/2017 6:12:16 AM
Incyte (INCY) Release: New Data For Presentation At ASCO 2017 Reinforce Clinical Profile Of Epacadostat In Combination With Keytruda® (Pembrolizumab) 5/18/2017 8:30:35 AM
Incyte (INCY) First Data From Combination Of Epacadostat With Opdivo (Nivolumab) Will Be Highlighted At ASCO 2017 5/18/2017 8:26:39 AM
Incyte (INCY) Reports 2017 First-Quarter Financial Results And Updates On Key Clinical Programs 5/4/2017 6:31:25 AM
Incyte (INCY)'s Immuno-Oncology And Targeted Therapy Clinical Portfolio To Be Featured In More Than 15 Abstracts At The 2017 ASCO Annual Meeting 4/21/2017 6:53:36 AM
12345678910...
//-->